We hypothesized that liraglutide attenuates DCM by modulating the ILK/PI3K/AKT signaling pathway and conducted this study to test our hypothesis in rats with streptozotocin (STZ)-induced T2DM. This evidence concerns the gene ILK and type 2 diabetes mellitus.